Navigation Links
GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
Date:3/30/2009

RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) has entered into a co-promotion agreement with Shire plc (LSE: SHP, Nasdaq: SHPGY) for Vyvanse(R), to help improve the recognition and treatment of adult Attention Deficit Hyperactivity Disorder (ADHD). This 3-year agreement covers the United States only and will add an important product to the GSK Neurosciences portfolio.

"GSK has been active in discovering and developing medicines to treat psychiatric disorders for decades, and neuroscience is one of the company's key therapeutic categories," said Deirdre Connelly, President, GlaxoSmithKline North American Pharmaceuticals. "Our professional

sales representatives are well positioned to provide physicians with information on the treatment of adult ADHD with Vyvanse and we look forward to helping meet the needs of adult patients with ADHD."

"Shire believes GSK is our ideal partner to promote Vyvanse because of its strength and leadership in CNS treatments," said Michael Cola, President of Shire's Specialty Pharmaceuticals business. "By collaborating with GSK, we are better positioned to reach psychiatrists and primary care physicians with treatment information about adult ADHD."

The GSK sales force is expected to begin promoting Vyvanse to physicians in May 2009.

Vyvanse is a prodrug of dextroamphetamine, a stimulant, which is therapeutically inactive until metabolized in the body. Vyvanse is currently available in six dosage strengths o
'/>"/>

SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
11. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... Modesto, CA (PRWEB) July 28, 2014 At ... an uncomfortable situation where they’re forced to contact the authorities. ... little more difficult than it initially seems. , Not every ... a vehicle get stolen, a person get mugged, or a ... little less obvious, leading onlookers to be more passive than ...
(Date:7/28/2014)... Researchers from Boston University School of Medicine (BUSM) report ... the risk of developing Alzheimer,s disease (AD). The discovery ... drug treatment options that target PLXNA4 specifically. These findings ... AD is the most frequent age-related dementia affecting 5.4 ... and older, and more than 40 percent of people ...
(Date:7/28/2014)... 28, 2014 Qualis Health, one ... management organizations, has published a complimentary, online toolkit ... engaging patients and families in infection control. ... hospitals, the toolkit provides a step-by-step roadmap for ... and their families early in a hospital stay. ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market ... North America with analysis and forecast of revenue. This market ... to $812.7 million by 2018, at a CAGR of 7.1% ... the North America Carotenoids & Antioxidants Market report to get ... a glimpse of the segmentation in the market, and is ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... Scientists at Warwick Medical School have uncovered the molecular ... ,health checkpoint, with cells that carry unequal numbers of ... , Studying simple yeast cells, scientists now understand the ... the correct number of chromosomes. , Most ...
... State University will lead a four-year, $5 million expanded ... discover proteins, or biomarkers, to help predict cardiovascular disease ... type 2 diabetes. Nearly 26 million Americans have ... U.S. The disease is a major cause of heart ...
... , TUESDAY, Nov. 1 (HealthDay News) -- Multiple sclerosis ... aim at the abnormal behavior of a specific type of ... the cells in question -- known as "B cells" -- ... and disabling nervous system disease, commonly called MS. The ...
... high school students are considered overweight, and while a myriad ... parents can do to help curb these rates, very little ... lose weight. Research led by public health doctoral candidate ... Philadelphia report wanting to lose weight, their actions are more ...
... an eight hour shift leads to substantial cost savings and energy ... Journal of the American College of Radiology . ... the use of computers and scanning equipment. "We should ... this equipment and look for ways to reduce it, both as ...
... NYU Langone Medical Center identified for the first time that ... outer and inner layers of the brain, called "blurring", may ... development of new therapies for degenerative brain conditions, such as ... issue of the Journal of Neuroscience . ...
Cached Medicine News:Health News:Warwick scientists discover how daughter cells receive the same number of chromosomes 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 3Health News:New Multiple Sclerosis Therapy Promising in Early Trial 2Health News:New Multiple Sclerosis Therapy Promising in Early Trial 3Health News:Study finds overweight teens want to lose weight, going about it the wrong way 2Health News:Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease 2
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/27/2014)... July 27, 2014 /PRNewswire-iReach/ -- This is ... Global and Chinese Vardenafil (CAS 224785-90-4) industry. ... of Vardenafil (CAS 224785-90-4) including its classification, ... explores global and China,s top manufacturers of ... capacity, production value, cost, gross margin and ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: